Two Alzheimer’s drugs help patients live independently at home for longer periods
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.
She knew she might get Alzheimer's in her 30s. That didn't make it any easier.
Jaime Bortz, 39, is losing her memory to dementia. Her mom, now a full-time carer, is foreshadowing the burden many families ...
Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Leqembi® sales reaches €200 million - first sales milestone achieved
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...
Pharmabiz4d
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment
Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...
Mena FN5d
Leqembi® Sales Reaches €200 Million - First Sales Milestone Achieved
Eisai is responsible for the clinical development, applications for market approval and commercialization of Lecanemab for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in ...
Medpage Today on MSN4d
Alzheimer's Patients May Gain Months of Independent Living With Treatment
Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...
pharmaphorum4d
Alzheimer's drug Leqembi to launch at discount to Aduhelm
Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...